Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
Daiichi Sankyo
Daiichi Sankyo
Nuvalent Inc.
Novartis
Novartis
Aveni Foundation
Nuvalent Inc.
AbbVie
AbbVie
xCures
NanOlogy, LLC
Nuvation Bio Inc.
Regeneron Pharmaceuticals
Amgen
Second Life Therapeutics
Daiichi Sankyo
Janssen Research & Development, LLC
Daiichi Sankyo
Merus B.V.